Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study

Inclusion Criteria: * Type 2 diabetic males \& females between 18-65 years. * HbA1c: 7.0% - 10.0% * Patient uncontrolled on oral anti-diabetics and lifestyle modifications for at least 3 months. * eGFR \>60 mL/min/1.73m2. * Patient who will give informed consent * Patient who are SGLT2i naïve Exclusion Criteria: * History of severe hypoglycemia for the last three months (\<70mg/dL) * Pregnant or lactating females * History of renal and/or hepatic dysfunctions, where RFT and Urine R/E is abnormal * History of recurrent urinary tract infection (UTI) and/or past 3 months' history of UTI and its treatment * Patients who have been admitted to the hospital in the past 3 months for diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state. * History of acute coronary syndrome or myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack. * History of active liver disease, including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease * Patient with diabetic foot ulcers